Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial

Authors: William J Sandborn, Julian Panés, Silvio Danese, Zaineb Sharafali, Azra Hassanali, Rhian Jacob-Moffatt, Christopher Eden, Marco Daperno, John F Valentine, David Laharie, Carolina Baía, Raja Atreya, Remo Panaccione, Grazyna Rydzewska, Humberto Aguilar, Séverine Vermeire

Published: 2022-10-12

DOI: 10.1016/s2468-1253(22)00303-x

Source: Full article

---

Abstract

No abstract found.